Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicting which subsets of patients with myelodysplastic neoplasms are more likely to progress to overt chronic myelomonocytic leukemia.

Leukemia & lymphoma - 1 Dec 2024

Tran Quang Violaine, Wagner-Ballon Orianne, Sloma Ivan

Abstract excerpt

The boundary between myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) has been revised in the latest World Health Organization classification of myeloid malignancies. These changes were motivated by the description of a subgroup of MDS patients identified as oligomonocytic chronic myelomonocytic leukemia (OM-CMML) at risk of evolving into overt CMML. Various studies will be reviewed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Dioxygenases
Share to Disease Progression

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA-Binding Proteins

Share to Leukemia, Myelomonocytic, Chronic

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Prognosis

Source

Identifiers

PMID: 39004904
DOI: 10.1080/10428194.2024.2378816

Genes

TET2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting which subsets of patients with myelodysplastic neoplasms are more likely to progress to overt chronic myelomonocytic leukemia.PMID 39004904Read ↗

Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.Semantic proximity Read ↗

Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and managementSemantic proximity Read ↗

Chronic Myelomonocytic Leukemia: History, Pathobiology, Diagnostic Controversies, and Evolving Classification.Semantic proximity Read ↗

Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.Semantic proximity Read ↗

How I diagnose and treat chronic myelomonocytic leukemia.Semantic proximity Read ↗

Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovationsSemantic proximity Read ↗

Incorporation of Genomic Determinants Improves Diagnostic Accuracy of Oligomonocytic Chronic Myelomonocytic Leukemia.Semantic proximity Read ↗

Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes.Semantic proximity Read ↗

Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.Semantic proximity Read ↗

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasmsSemantic proximity Read ↗

Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological reviewSemantic proximity Read ↗

Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.